Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs

Key Takeaways Exact Sciences unveiled Cancerguard, a new multi-cancer early detection blood test in the United States.EXAS' Cancerguard showed 64% sensitivity across cancers and 97.4% specificity to limit false positives.The company is enrolling 25,000 in the Falcon study to support coverage and future FDA submissions.Exact Sciences Corporation (EXAS) has launched the Cancerguard test, a new multi-cancer early detection (MCED) blood test now offered as a laboratory-developed test (LDT) in the United States. ...